Axogen, Inc. · NASDAQ:AXGN

Axogen — Merger or Acquisition (September 2026)

15 slides from Axogen's merger presentation, Sep 10, 2026

  1. Slide 1: Making Nerve Repair an Expected Standard of Care: Company Overview

    Making Nerve Repair an Expected Standard of Care Company Overview​ September 2026

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995, which are statements that are not historical facts and relate to future conditions, events, or results. These statements are based on management's cu

  3. Slide 3: Our Mission

    To restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care. Our Mission 2

  4. Slide 4: Large and Underserved Potential: $5.6B U.S. Nerve Care Opportunity

    Large and Underserved Potential $5.6B U.S. Nerve Care Opportunity More than 1.5 million peripheral nerve injuries a year in the U.S. require treatment in Axogen focus markets1,2,3,7 Extremities Market Every year patients suffer from 700,000 traumatic nerve injuries and more than 370,000 chronic nerv

  5. Slide 5: The Axogen Nerve Repair Algorithm

    The Axogen Nerve Repair Algorithm Connection Protection Termination 4

  6. Slide 6: Accelerating Topline Drives Operational Leverage

    Accelerating Topline Drives Operational Leverage Accelerating Revenue Growth Expanding EBITDA 2022 2023 2024 2025 $138.6 $159.0 $187.3 $225.2 ($25.6) ($15.5) $3.9 ($2.2) ($9.3) ($1.1) $19.8 $27.9 ($30.0) ($20.0) ($10.0) $0.0 $10.0 $20.0 $30.0 $40.0 EBITDA Adj. EBITDA* 2022 2023 2024 2025 *Excludes n

  7. Slide 7: 2025-2028 Strategic Plan Priorities

    2025-2028 Strategic Plan Priorities Strong momentum and execution of strategic plan priorities. Growth CAGR 15 - 20% Markets Elective and planned procedure focus Prostate market development Commercial Expansion Commercial infrastructure and salesforce expansion Commercial Excellence Continuous busin

  8. Slide 8: BioCircuit Technologies At-a-Glance

    BioCircuit Technologies At-a-Glance ~$24MM Run-Rate Revenue (Q2 2026 Annualized) KEY STATISTICS Commercializes NerveTape, the first FDA-cleared device for sutureless nerve repair Cost-efficient GTM model Strong visibility across surgeon networks Traction across markets and specialties ✓ ✓ ✓ ✓ 14,000

  9. Slide 9: Challenges with Suture-Based Nerve Repair

    Time-consuming Highly skill-dependent Suture trauma Poor alignment is common - even by experienced surgeons 40% of cadaver repairs are unacceptable1 1. Bernstein et al. JHS 2013; Isaacs et al. JHS 2016 Challenges with Suture- Based Nerve Repair 8

  10. Slide 10: NerveTape: First FDA-cleared Device for Sutureless Nerve Repair

    Precisely align, connect, & protect transected nerves in a fraction of the time it would take to repair using conventional suture and conduit techniques Easily repair & connect transected nerves Eliminate the need for microsuture Nerve Tape is designed to: Eberlin KR, Safa B, Buntic RF, et al. Usabi

  11. Slide 11: NerveTape vs. Microsuture

    NerveTape vs. MicrosutureLink: 10

  12. Slide 12: Strategic Rationale

    • Simpler, faster, more effective alternative to micro-suturing in nerve repair • Less dependency on microsurgical skills enables expansion and adoption of nerve repair to non-specialist surgeons and middle-adopters • Foundational technology base for future product development and indication expansi

  13. Slide 13: Purchase Price and Key Financial Metrics

    PURCHASE PRICE $ 2 0 0 M I L L I O N I N C A S H , S U B J E C T T O C U S T O M A R Y A D J U S T M E N T S KEY FINANCIAL METRICS • ~ $ 2 4 M M R U N - R A T E R E V E N U E Q 2 2 0 2 6 A N N U A L I Z E D ( $ 1 1 M M I N 2 0 2 5 ) • E X P E C T E D T O B E A C C R E T I V E T O R E V E N U E G R O

  14. Slide 14: Our Investment Thesis is Reinforced by this Acquisition

    Our Investment Thesis is Reinforced by this Acquisition Large Market Opportunity $5.6B TAM with minimal current penetration Clinical Leadership Unique and differentiated nerve repair portfolio backed by strong evidence Multiple Growth Catalysts Four distinct market development opportunities at diffe

  15. Slide 15: Thank You

    Thank You © 2026 Axogen Corporation. All rights reserved. The stylized "a" logo is a registered trademark of Axogen Corporation.

Axogen — Merger or Acquisition (September 2026) on 6ix